About Inotec AMD

Working with nature to heal wounds
Oxygen and Wound Healing

One of the vital factors that determine the healing of wounds is the availability of oxygen at the site of repair. Hypoxia is one of the main reasons for increased time required for wound healing, as the damaged skin or the pre-existing illness, such as diabetes, prevents sufficient oxygen from reaching the wound. It is estimated that, in Germany alone, around 4 million wounds per year stagnate in the process of healing despite being treated according to gold standards for therapy.

Wound healing requires restoration of microcirculation to restore and replace injured vessels. The main, or at least the most “immediate” requirement is oxygen, which is critically important for reconstruction of new vessels and connective tissue and provision of a competent resistance against infection.(1.2.)

    1. Gottrup F. Oxygen in wound healing and infection. World J Surg 2004; 28: 312-315.
    2. Niinikoski J, Gottrup F, Hunt TK. The role of oxygen in wound repair. In: Janssen H, Rooman R, Robertson JIS (eds). Wound healing. Blackwell Scientific publications, Oxford. 1991:165-174.

The problem has been – how do you provide a continuous supply of pure humidified oxygen to a patient’s wound without impairing their daily activities and at the lowest cost possible?

To solve this problem – Inotec AMD developed the NATROX® device. NATROX® works by supplying a high concentration of pure oxygen to the skin and wound bed under the dressing. This device creates a continuous oxygen-enriched atmosphere around the wound area in order to accelerate the wound healing process. As the current trend in the global wound care market is to shift wound healing therapy from hospital/clinical settings to the home setting, NATROX® has been specifically designed to meet this growing ambulatory demand.

NATROX® is a small portable device – about the size of a mobile phone. Its lightweight and compact size allow it to be highly portable, thereby making it an ideal therapy device to be prescribed in homecare settings for the faster treatment of chronic wounds.


All chronic pain, suffering, and diseases are caused by a lack of oxygen at the cell level3

Overview of the NATROX® Oxygen Delivery System (ODS) Class II b CE marked.

The advantages of topically applying pure humidified oxygen at above atmosphere pressure directly to a wound surface are well established. The challenge which Inotec AMD faced was to achieve this while allowing free and unhindered transmission of wound fluids (exudate) away from the wound.

Typically lower leg ulcers and non-healing surgical wounds are dressed to absorb and retain exudate, protect from infection and resist impact damage. Patients with oedema require additional compression bandaging. These combine to isolate and seal the wound from the 21% of natural oxygen present in air. Wounds cannot heal without oxygen; a catalyst for the regeneration of new tissue with antimicrobial and pain reducing features.

The NATROX® system provides a continuous low flow of pure humidified oxygen directly to the wound surface, constantly refreshing the wound whilst ensuring full mobility.

Wounds produce varying levels of wound fluid, which if not managed will cause maceration and damage to the surrounding skin. Successfully applying oxygen to a wound surface requires:

  • Direct contact with the wound surface.
  • No restrictions to the outflow of exudate from the wound.
  • Ease of application with no trauma or damage when removed.
  • Comfortable and unnoticed by the patient.
  • Allow a choice of dressing selected by the Clinician.

Research and evaluation results confirm a unique method of applying oxygen directly to the wound surface. Safety trials confirm the ODS is comfortable, easy to apply and present no trauma when removed.

The unique ODS construction ensures an oxygen pathway distributing oxygen even when 3 layer compressed bandaging is used.

The top layer is a barrier to oxygen, the lower (wound side) is hydrophobic yet highly permeable to oxygen. After connection, the oxygen flow creates an oxygen rich environment which permeates the lower layer directly in contact with the wound surface.

The 'web' design allows for the free passage of exudate even at extreme levels. This enables exudate to be absorbed and retained in a range of dressings. These dressings may be 'active', for example honey, zinc etc.

The Oxygen Generator (OG) was conceived and a working prototype demonstrated in the Department of Materials Science and Metallurgy and patent protection by the University of Cambridge. Responsibility for this was transferred to Inotec AMD where it was redesigned into a commercial product and a licence granted by the University of Cambridge.

    3. Dr. Arthur C. Guyton, M.D., author "The Textbook on Medical Physiology".


Dr Adrian Parton MBE

Chad Bateman
Chief Executive Officer  

Dr Paul Hayes
Chief Medical Officer

Board of Management

Adrian Parton

Chad Bateman
Chief Executive Officer

Nick Hyde
Non Executive Director

Pierre Socha
Non Executive Director 

Michael Clancy
Non Executive Director

Luigi Sala
Non Executive Director
Joanna Musk
Company Secretary



Cambridge Capital Group

Cambridge Capital Group is a leading business angel group of 40 investors that have been investing in hi-tech businesses for ten years.

Cambridge Enterprise

Cambridge Enterprise Limited is a wholly owned subsidiary of the University of Cambridge, responsible for the commercialisation of University intellectual property.

Cambridge Angels

The Cambridge Angels are a group of high-net worth investors who have proven experience as successful entrepreneurs in technology and bio-technology.

Amadeus Capital Partners

Amadeus Capital Partners is a global technology investor. Since its inception in 1997, the firm has raised over $1bn for investment and backed more than 100 companies in the software, mobile, internet, cyber security and medical technology sectors. The investment team is based in India, South Africa, Sweden, UK and USA, has deep experience in technology and invests in high-growth companies from early stage to pre-IPO.